Tesseract Medicines Secures $20 Million in Seed Funding to Advance Covalent Induced Drug Conjugates

Recently, Tesseract Medicines announced the successful completion of a $20 million seed funding round, aimed at advancing its next-generation targeted therapy—Covalent Induced Drug Conjugates (CIDCs). The round was co-led by Curie.Bio, Geding Venture Capital, and Chengwei Capital.

Building on the latest advances in antibody-drug conjugates (ADCs) and covalent inhibitors, Mofang Bio is pioneering a novel therapeutic approach that specifically targets cancer-associated intracellular proteins, enabling precise delivery of cytotoxic payloads and ushering in a new era of precision medicine.

As a global leader in life sciences innovation, Geding Ventures boasts a strong management team with strategic positioning in the United States and China, leveraging its unique incubator model. We engage in complementary collaborations with top-tier scientists and visionary entrepreneurs, applying our expertise to validate and realize groundbreaking biopharmaceutical solutions. Our unwavering mission is straightforward: to lead transformative science by founding and co-founding companies that combine advanced scientific methodologies with unparalleled industry leadership. At Geding Ventures, we are firmly committed to uncovering pioneering therapeutic strategies that will deliver profound benefits to global human health.